Study identifies potential noninvasive biomarkers in NAFLD, NASH using Metabolon's platform

Metabolon, Inc. announces a study published in the Metabolism Journal released in the paper on April 28, 2010, by Satish C. Kalhan.

Metabolon, Inc., the leader in global metabolism, biomarker discovery and analysis, studied plasma profiles from subjects with nonalcoholic fatty liver disease (NAFLD). Using Metabolon's patented global metabolomic profiling platform, the study, authored by Satish C. Kalhan and his collaborators at the Cleveland Clinic and Case Western Reserve University School of Medicine and with scientists from Metabolon, identified a panel of potential noninvasive biomarkers in NAFLD and Nonalcoholic Steatohepatitis (NASH). The results represent both a significant step in understanding the disease and for the development of therapeutic interventions.

Nonalcoholic steatohepatitis (NASH) is described as inflammation of the liver associated with the accumulation of fat in the liver. NAFLD and NASH occur in individuals who do not consume excessive amounts of alcohol, yet has similarities in what can be seen in liver disease with an excessive intake of alcohol.


Metabolon, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Green Mediterranean diet reshapes DNA methylation, boosts metabolism